# reload+after+2024-01-23 11:47:15.884272
address1§Times Square Tower
address2§Suite 2503 7 Times Square
city§New York
state§NY
zip§10036
country§United States
phone§646 200 5278
website§https://www.sellaslifesciences.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.
fullTimeEmployees§17
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Angelos M. Stergiou M.D., ScD h.c.', 'age': 47, 'title': 'Founder, President, CEO & Director', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 921985, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Barbara A. Wood Esq.', 'age': 60, 'title': 'Executive VP, General Counsel & Corporate Secretary', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 632660, 'exercisedValue': 0, 'unexercisedValue': 8078}, {'maxAge': 1, 'name': 'Mr. Robert M. Francomano', 'age': 56, 'title': 'Senior VP & Chief Commercial Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 667354, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John Thomas Burns CPA', 'age': 38, 'title': 'Senior VP & CFO', 'yearBorn': 1985, 'fiscalYear': 2022, 'totalPay': 338446, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Dragan  Cicic M.D., MBA', 'age': 60, 'title': 'Senior Vice President of Clinical Development', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 466430, 'exercisedValue': 0, 'unexercisedValue': 55739}, {'maxAge': 1, 'name': 'Mr. Andrew  Elnatan', 'title': 'VP and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & Quality', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§2.253
priceToSalesTrailing12Months§Infinity
currency§USD
dateShortInterest§1702598400
forwardEps§-0.96
exchange§NCM
quoteType§EQUITY
shortName§SELLAS Life Sciences Group, Inc
longName§SELLAS Life Sciences Group, Inc.
firstTradeDateEpochUtc§1205328600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§d5f0c150-9f89-3f17-8497-1832af4e7670
gmtOffSetMilliseconds§-18000000
targetHighPrice§9.0
targetLowPrice§4.0
targetMeanPrice§7.0
targetMedianPrice§8.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§0.338
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
